RheoSwitch Therapeutic System (RTS) gene switch receptor (RTS)

The RheoSwitch Therapeutic System (RTS) is a proprietary, ligand-inducible gene regulation platform designed to provide precise control over the expression of therapeutic transgenes in vivo. The system is centered on a modified insect ecdysone receptor (EcR) that functions as a heterodimer with a partner protein, often a chimeric version of the human retinoid X receptor (RXR) (Karzenowski et al., 2005). In its inactive state, the receptor complex does not initiate transcription; however, upon the administration of a specific small-molecule inducer like Veledimex (RG-115830), the ligand binds to the EcR subunit, inducing a conformational change that recruits co-activators and initiates the transcription of the target gene (Chiocca et al., 2019). This technology is particularly significant in the field of immuno-oncology, where it is used to control the production of potent cytokines such as Interleukin-12 (IL-12) to treat solid tumors like glioblastoma while minimizing systemic side effects (Precigen, 2024). By modulating the dose of the oral inducer, clinicians can effectively turn on or turn off the therapeutic effect, providing a safety switch and a means to optimize the therapeutic window (Barrett et al., 2018). The RTS represents a sophisticated approach to gene therapy that addresses the challenges of dose-limiting toxicities associated with constitutive expression of potent biological agents.

Other names

Ecdysone receptor (EcR)RTSRheoSwitchVeledimex-inducible gene switchEcR-RXR heterodimer

Ligand-inducible transcriptional activation where a small-molecule inducer binds to a chimeric ecdysone receptor complex, enabling it to bind to specific DNA response elements and drive the expression of a therapeutic transgene.